nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—L-DOPA—Melphalan—peripheral nervous system neoplasm	0.64	1	CrCrCtD
Methyldopa—DDC—Catecholamine biosynthesis—TH—peripheral nervous system neoplasm	0.0139	0.159	CbGpPWpGaD
Methyldopa—DDC—Parkinsons Disease Pathway—PINK1—peripheral nervous system neoplasm	0.0115	0.132	CbGpPWpGaD
Methyldopa—Metyrosine—TH—peripheral nervous system neoplasm	0.00967	1	CrCbGaD
Methyldopa—COMT—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—peripheral nervous system neoplasm	0.00756	0.0863	CbGpPWpGaD
Methyldopa—DDC—Dopamine metabolism—TH—peripheral nervous system neoplasm	0.00543	0.062	CbGpPWpGaD
Methyldopa—DDC—Biogenic Amine Synthesis—TH—peripheral nervous system neoplasm	0.00484	0.0553	CbGpPWpGaD
Methyldopa—COMT—Dopamine metabolism—TH—peripheral nervous system neoplasm	0.00482	0.0551	CbGpPWpGaD
Methyldopa—DDC—Amine-derived hormones—TH—peripheral nervous system neoplasm	0.0046	0.0525	CbGpPWpGaD
Methyldopa—COMT—Biogenic Amine Synthesis—TH—peripheral nervous system neoplasm	0.0043	0.0491	CbGpPWpGaD
Methyldopa—DDC—Nicotine Activity on Dopaminergic Neurons—TH—peripheral nervous system neoplasm	0.0037	0.0422	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00282	0.0322	CbGpPWpGaD
Methyldopa—DDC—Dopaminergic Neurogenesis—TH—peripheral nervous system neoplasm	0.00278	0.0318	CbGpPWpGaD
Methyldopa—DDC—Parkinsons Disease Pathway—TH—peripheral nervous system neoplasm	0.0023	0.0263	CbGpPWpGaD
Methyldopa—DDC—Parkinsons Disease Pathway—CASP3—peripheral nervous system neoplasm	0.000936	0.0107	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.000811	0.00927	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.000743	0.00849	CbGpPWpGaD
Methyldopa—DDC—Amino acid and derivative metabolism—TH—peripheral nervous system neoplasm	0.00064	0.00732	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.000607	0.00693	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.000606	0.00692	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (z) signalling events—GNAS—peripheral nervous system neoplasm	0.000579	0.00661	CbGpPWpGaD
Methyldopa—DDC—nerve—peripheral nervous system neoplasm	0.000576	0.247	CbGeAlD
Methyldopa—COMT—Transmission across Chemical Synapses—BCHE—peripheral nervous system neoplasm	0.000575	0.00658	CbGpPWpGaD
Methyldopa—DDC—ganglion—peripheral nervous system neoplasm	0.000569	0.244	CbGeAlD
Methyldopa—DDC—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.00054	0.00617	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.0005	0.00572	CbGpPWpGaD
Methyldopa—Jaundice—Etoposide—peripheral nervous system neoplasm	0.000485	0.00186	CcSEcCtD
Methyldopa—Mental disorder—Vincristine—peripheral nervous system neoplasm	0.000483	0.00186	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Melphalan—peripheral nervous system neoplasm	0.000482	0.00185	CcSEcCtD
Methyldopa—Paraesthesia—Isotretinoin—peripheral nervous system neoplasm	0.000482	0.00185	CcSEcCtD
Methyldopa—Paraesthesia—Tretinoin—peripheral nervous system neoplasm	0.000482	0.00185	CcSEcCtD
Methyldopa—Leukopenia—Dactinomycin—peripheral nervous system neoplasm	0.000481	0.00185	CcSEcCtD
Methyldopa—Connective tissue disorder—Cisplatin—peripheral nervous system neoplasm	0.000479	0.00184	CcSEcCtD
Methyldopa—Colitis—Epirubicin—peripheral nervous system neoplasm	0.000479	0.00184	CcSEcCtD
Methyldopa—Paraesthesia—Melphalan—peripheral nervous system neoplasm	0.000475	0.00183	CcSEcCtD
Methyldopa—Hepatobiliary disease—Etoposide—peripheral nervous system neoplasm	0.00047	0.00181	CcSEcCtD
Methyldopa—ADRA2A—Regulation of insulin secretion—SLC2A1—peripheral nervous system neoplasm	0.000468	0.00535	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.000467	0.0018	CcSEcCtD
Methyldopa—Agranulocytosis—Etoposide—peripheral nervous system neoplasm	0.000464	0.00179	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.000463	0.00178	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.000463	0.00178	CcSEcCtD
Methyldopa—Constipation—Topotecan—peripheral nervous system neoplasm	0.000462	0.00178	CcSEcCtD
Methyldopa—Hepatocellular injury—Doxorubicin—peripheral nervous system neoplasm	0.000461	0.00177	CcSEcCtD
Methyldopa—Constipation—Tretinoin—peripheral nervous system neoplasm	0.000459	0.00176	CcSEcCtD
Methyldopa—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.000459	0.00176	CcSEcCtD
Methyldopa—Myalgia—Dactinomycin—peripheral nervous system neoplasm	0.000457	0.00176	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.000457	0.00176	CcSEcCtD
Methyldopa—Cardiac disorder—Cisplatin—peripheral nervous system neoplasm	0.000452	0.00174	CcSEcCtD
Methyldopa—COMT—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000444	0.00507	CbGpPWpGaD
Methyldopa—Colitis—Doxorubicin—peripheral nervous system neoplasm	0.000443	0.0017	CcSEcCtD
Methyldopa—COMT—Neuronal System—BCHE—peripheral nervous system neoplasm	0.000441	0.00504	CbGpPWpGaD
Methyldopa—Mediastinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000439	0.00169	CcSEcCtD
Methyldopa—Oedema—Dactinomycin—peripheral nervous system neoplasm	0.000438	0.00169	CcSEcCtD
Methyldopa—Infection—Dactinomycin—peripheral nervous system neoplasm	0.000436	0.00167	CcSEcCtD
Methyldopa—Leukopenia—Vincristine—peripheral nervous system neoplasm	0.00043	0.00165	CcSEcCtD
Methyldopa—Thrombocytopenia—Dactinomycin—peripheral nervous system neoplasm	0.000429	0.00165	CcSEcCtD
Methyldopa—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000427	0.00164	CcSEcCtD
Methyldopa—Arthralgia—Alitretinoin—peripheral nervous system neoplasm	0.000424	0.00163	CcSEcCtD
Methyldopa—Myalgia—Alitretinoin—peripheral nervous system neoplasm	0.000424	0.00163	CcSEcCtD
Methyldopa—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000424	0.00163	CcSEcCtD
Methyldopa—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000424	0.00163	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000421	0.00162	CcSEcCtD
Methyldopa—Flatulence—Cisplatin—peripheral nervous system neoplasm	0.000418	0.00161	CcSEcCtD
Methyldopa—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.000414	0.00159	CcSEcCtD
Methyldopa—Myalgia—Vincristine—peripheral nervous system neoplasm	0.000409	0.00157	CcSEcCtD
Methyldopa—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.000406	0.00156	CcSEcCtD
Methyldopa—Angiopathy—Etoposide—peripheral nervous system neoplasm	0.000405	0.00156	CcSEcCtD
Methyldopa—Infection—Alitretinoin—peripheral nervous system neoplasm	0.000404	0.00155	CcSEcCtD
Methyldopa—Eczema—Epirubicin—peripheral nervous system neoplasm	0.000403	0.00155	CcSEcCtD
Methyldopa—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000402	0.00155	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000399	0.00154	CcSEcCtD
Methyldopa—Cardiac failure congestive—Epirubicin—peripheral nervous system neoplasm	0.000399	0.00153	CcSEcCtD
Methyldopa—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.000399	0.00153	CcSEcCtD
Methyldopa—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000398	0.00153	CcSEcCtD
Methyldopa—Thrombocytopenia—Alitretinoin—peripheral nervous system neoplasm	0.000398	0.00153	CcSEcCtD
Methyldopa—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000395	0.00152	CcSEcCtD
Methyldopa—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000395	0.00152	CcSEcCtD
Methyldopa—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000395	0.00152	CcSEcCtD
Methyldopa—Oedema—Vincristine—peripheral nervous system neoplasm	0.000392	0.00151	CcSEcCtD
Methyldopa—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.00039	0.0015	CcSEcCtD
Methyldopa—Infection—Vincristine—peripheral nervous system neoplasm	0.000389	0.0015	CcSEcCtD
Methyldopa—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000388	0.00149	CcSEcCtD
Methyldopa—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000385	0.00148	CcSEcCtD
Methyldopa—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000385	0.00148	CcSEcCtD
Methyldopa—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000384	0.00148	CcSEcCtD
Methyldopa—Thrombocytopenia—Vincristine—peripheral nervous system neoplasm	0.000383	0.00147	CcSEcCtD
Methyldopa—Leukopenia—Cisplatin—peripheral nervous system neoplasm	0.00038	0.00146	CcSEcCtD
Methyldopa—Asthenia—Melphalan—peripheral nervous system neoplasm	0.00038	0.00146	CcSEcCtD
Methyldopa—ADRA2A—Regulation of insulin secretion—GNAS—peripheral nervous system neoplasm	0.000377	0.0043	CbGpPWpGaD
Methyldopa—COMT—ganglion—peripheral nervous system neoplasm	0.000376	0.161	CbGeAlD
Methyldopa—Eczema—Doxorubicin—peripheral nervous system neoplasm	0.000373	0.00143	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.00037	0.00142	CcSEcCtD
Methyldopa—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00037	0.00142	CcSEcCtD
Methyldopa—Cardiac failure congestive—Doxorubicin—peripheral nervous system neoplasm	0.000369	0.00142	CcSEcCtD
Methyldopa—ADRA2A—Integration of energy metabolism—SLC2A1—peripheral nervous system neoplasm	0.000368	0.00421	CbGpPWpGaD
Methyldopa—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000367	0.00141	CcSEcCtD
Methyldopa—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000367	0.00141	CcSEcCtD
Methyldopa—Paraesthesia—Alitretinoin—peripheral nervous system neoplasm	0.000365	0.0014	CcSEcCtD
Methyldopa—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000362	0.00139	CcSEcCtD
Methyldopa—SLC15A1—SLC-mediated transmembrane transport—SLC2A1—peripheral nervous system neoplasm	0.000362	0.00413	CbGpPWpGaD
Methyldopa—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.000361	0.00139	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000359	0.00138	CcSEcCtD
Methyldopa—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000358	0.00138	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.000357	0.00137	CcSEcCtD
Methyldopa—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000355	0.00136	CcSEcCtD
Methyldopa—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000355	0.00136	CcSEcCtD
Methyldopa—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.000352	0.00135	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000351	0.00135	CcSEcCtD
Methyldopa—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.000348	0.00134	CcSEcCtD
Methyldopa—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.000348	0.00134	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000347	0.00397	CbGpPWpGaD
Methyldopa—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000347	0.00133	CcSEcCtD
Methyldopa—Oedema—Cisplatin—peripheral nervous system neoplasm	0.000346	0.00133	CcSEcCtD
Methyldopa—Infection—Cisplatin—peripheral nervous system neoplasm	0.000344	0.00132	CcSEcCtD
Methyldopa—Vomiting—Topotecan—peripheral nervous system neoplasm	0.000344	0.00132	CcSEcCtD
Methyldopa—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.000341	0.00131	CcSEcCtD
Methyldopa—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.000341	0.00131	CcSEcCtD
Methyldopa—Rash—Topotecan—peripheral nervous system neoplasm	0.000341	0.00131	CcSEcCtD
Methyldopa—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.000341	0.00131	CcSEcCtD
Methyldopa—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.00034	0.00131	CcSEcCtD
Methyldopa—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.000339	0.0013	CcSEcCtD
Methyldopa—Headache—Topotecan—peripheral nervous system neoplasm	0.000339	0.0013	CcSEcCtD
Methyldopa—Rash—Tretinoin—peripheral nervous system neoplasm	0.000338	0.0013	CcSEcCtD
Methyldopa—Rash—Isotretinoin—peripheral nervous system neoplasm	0.000338	0.0013	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000338	0.0013	CcSEcCtD
Methyldopa—DDC—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000338	0.00386	CbGpPWpGaD
Methyldopa—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.000338	0.0013	CcSEcCtD
Methyldopa—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.000338	0.0013	CcSEcCtD
Methyldopa—Vomiting—Melphalan—peripheral nervous system neoplasm	0.000337	0.00129	CcSEcCtD
Methyldopa—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000336	0.00129	CcSEcCtD
Methyldopa—Headache—Tretinoin—peripheral nervous system neoplasm	0.000336	0.00129	CcSEcCtD
Methyldopa—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000336	0.00129	CcSEcCtD
Methyldopa—Constipation—Vincristine—peripheral nervous system neoplasm	0.000335	0.00129	CcSEcCtD
Methyldopa—Liver function test abnormal—Epirubicin—peripheral nervous system neoplasm	0.000334	0.00128	CcSEcCtD
Methyldopa—Rash—Melphalan—peripheral nervous system neoplasm	0.000334	0.00128	CcSEcCtD
Methyldopa—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.000333	0.00128	CcSEcCtD
Methyldopa—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	0.00033	0.00127	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000329	0.00126	CcSEcCtD
Methyldopa—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000327	0.00126	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.000326	0.00125	CcSEcCtD
Methyldopa—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000323	0.00124	CcSEcCtD
Methyldopa—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000321	0.00124	CcSEcCtD
Methyldopa—Nausea—Topotecan—peripheral nervous system neoplasm	0.000321	0.00124	CcSEcCtD
Methyldopa—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000319	0.00123	CcSEcCtD
Methyldopa—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000319	0.00123	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000316	0.00121	CcSEcCtD
Methyldopa—Infection—Etoposide—peripheral nervous system neoplasm	0.000315	0.00121	CcSEcCtD
Methyldopa—Abdominal distension—Epirubicin—peripheral nervous system neoplasm	0.000315	0.00121	CcSEcCtD
Methyldopa—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000315	0.00121	CcSEcCtD
Methyldopa—Nausea—Melphalan—peripheral nervous system neoplasm	0.000314	0.00121	CcSEcCtD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000312	0.00357	CbGpPWpGaD
Methyldopa—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000311	0.0012	CcSEcCtD
Methyldopa—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.000311	0.00119	CcSEcCtD
Methyldopa—Eosinophilia—Epirubicin—peripheral nervous system neoplasm	0.00031	0.00119	CcSEcCtD
Methyldopa—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.00031	0.00119	CcSEcCtD
Methyldopa—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000309	0.00119	CcSEcCtD
Methyldopa—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000308	0.00119	CcSEcCtD
Methyldopa—Pancreatitis—Epirubicin—peripheral nervous system neoplasm	0.000307	0.00118	CcSEcCtD
Methyldopa—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000306	0.00118	CcSEcCtD
Methyldopa—Angina pectoris—Epirubicin—peripheral nervous system neoplasm	0.000305	0.00117	CcSEcCtD
Methyldopa—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000303	0.00116	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000303	0.00346	CbGpPWpGaD
Methyldopa—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.000301	0.00116	CcSEcCtD
Methyldopa—COMT—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.0003	0.00343	CbGpPWpGaD
Methyldopa—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.0003	0.00115	CcSEcCtD
Methyldopa—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000299	0.00115	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000299	0.00115	CcSEcCtD
Methyldopa—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.000297	0.00114	CcSEcCtD
Methyldopa—ADRA2A—Integration of energy metabolism—GNAS—peripheral nervous system neoplasm	0.000296	0.00338	CbGpPWpGaD
Methyldopa—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000292	0.00112	CcSEcCtD
Methyldopa—Abdominal distension—Doxorubicin—peripheral nervous system neoplasm	0.000291	0.00112	CcSEcCtD
Methyldopa—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000289	0.00111	CcSEcCtD
Methyldopa—Eosinophilia—Doxorubicin—peripheral nervous system neoplasm	0.000287	0.0011	CcSEcCtD
Methyldopa—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000285	0.0011	CcSEcCtD
Methyldopa—Weight increased—Epirubicin—peripheral nervous system neoplasm	0.000285	0.00109	CcSEcCtD
Methyldopa—Pancreatitis—Doxorubicin—peripheral nervous system neoplasm	0.000284	0.00109	CcSEcCtD
Methyldopa—Angina pectoris—Doxorubicin—peripheral nervous system neoplasm	0.000282	0.00108	CcSEcCtD
Methyldopa—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000281	0.00108	CcSEcCtD
Methyldopa—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000279	0.00107	CcSEcCtD
Methyldopa—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000279	0.00107	CcSEcCtD
Methyldopa—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000279	0.00107	CcSEcCtD
Methyldopa—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000278	0.00107	CcSEcCtD
Methyldopa—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000276	0.00106	CcSEcCtD
Methyldopa—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000275	0.00106	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000274	0.00105	CcSEcCtD
Methyldopa—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000274	0.00105	CcSEcCtD
Methyldopa—Jaundice—Epirubicin—peripheral nervous system neoplasm	0.000272	0.00105	CcSEcCtD
Methyldopa—Constipation—Etoposide—peripheral nervous system neoplasm	0.000271	0.00104	CcSEcCtD
Methyldopa—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000269	0.00103	CcSEcCtD
Methyldopa—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000268	0.00103	CcSEcCtD
Methyldopa—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000264	0.00101	CcSEcCtD
Methyldopa—Weight increased—Doxorubicin—peripheral nervous system neoplasm	0.000263	0.00101	CcSEcCtD
Methyldopa—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00026	0.001	CcSEcCtD
Methyldopa—Agranulocytosis—Epirubicin—peripheral nervous system neoplasm	0.00026	0.001	CcSEcCtD
Methyldopa—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000259	0.000996	CcSEcCtD
Methyldopa—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000258	0.000994	CcSEcCtD
Methyldopa—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000258	0.000992	CcSEcCtD
Methyldopa—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000258	0.000992	CcSEcCtD
Methyldopa—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000256	0.000986	CcSEcCtD
Methyldopa—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000256	0.000985	CcSEcCtD
Methyldopa—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000255	0.000981	CcSEcCtD
Methyldopa—Bradycardia—Epirubicin—peripheral nervous system neoplasm	0.000255	0.00098	CcSEcCtD
Methyldopa—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000255	0.000979	CcSEcCtD
Methyldopa—Jaundice—Doxorubicin—peripheral nervous system neoplasm	0.000252	0.000967	CcSEcCtD
Methyldopa—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000251	0.000965	CcSEcCtD
Methyldopa—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.00025	0.000963	CcSEcCtD
Methyldopa—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000249	0.000958	CcSEcCtD
Methyldopa—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000248	0.000956	CcSEcCtD
Methyldopa—DDC—brainstem—peripheral nervous system neoplasm	0.000247	0.106	CbGeAlD
Methyldopa—Rash—Vincristine—peripheral nervous system neoplasm	0.000247	0.00095	CcSEcCtD
Methyldopa—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000247	0.000949	CcSEcCtD
Methyldopa—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000246	0.000946	CcSEcCtD
Methyldopa—Headache—Vincristine—peripheral nervous system neoplasm	0.000245	0.000944	CcSEcCtD
Methyldopa—DDC—Metabolism—GNS—peripheral nervous system neoplasm	0.000244	0.00279	CbGpPWpGaD
Methyldopa—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000244	0.000938	CcSEcCtD
Methyldopa—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000241	0.000929	CcSEcCtD
Methyldopa—Agranulocytosis—Doxorubicin—peripheral nervous system neoplasm	0.000241	0.000926	CcSEcCtD
Methyldopa—ADRA2A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000238	0.00272	CbGpPWpGaD
Methyldopa—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000237	0.000911	CcSEcCtD
Methyldopa—Bradycardia—Doxorubicin—peripheral nervous system neoplasm	0.000236	0.000907	CcSEcCtD
Methyldopa—DDC—Metabolism—NME1—peripheral nervous system neoplasm	0.000234	0.00268	CbGpPWpGaD
Methyldopa—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000234	0.000899	CcSEcCtD
Methyldopa—Nausea—Vincristine—peripheral nervous system neoplasm	0.000233	0.000895	CcSEcCtD
Methyldopa—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.000232	0.000894	CcSEcCtD
Methyldopa—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000232	0.000891	CcSEcCtD
Methyldopa—ADRA2A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000228	0.0026	CbGpPWpGaD
Methyldopa—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000228	0.000875	CcSEcCtD
Methyldopa—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000228	0.000875	CcSEcCtD
Methyldopa—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000227	0.000873	CcSEcCtD
Methyldopa—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000226	0.000868	CcSEcCtD
Methyldopa—DDC—Metabolism—COX2—peripheral nervous system neoplasm	0.000225	0.00258	CbGpPWpGaD
Methyldopa—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00022	0.000847	CcSEcCtD
Methyldopa—Mental disorder—Epirubicin—peripheral nervous system neoplasm	0.000219	0.000843	CcSEcCtD
Methyldopa—Rash—Cisplatin—peripheral nervous system neoplasm	0.000218	0.00084	CcSEcCtD
Methyldopa—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000218	0.000839	CcSEcCtD
Methyldopa—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000217	0.000835	CcSEcCtD
Methyldopa—COMT—Metabolism—GNS—peripheral nervous system neoplasm	0.000217	0.00248	CbGpPWpGaD
Methyldopa—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000215	0.000827	CcSEcCtD
Methyldopa—Flatulence—Epirubicin—peripheral nervous system neoplasm	0.000215	0.000826	CcSEcCtD
Methyldopa—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.00021	0.000808	CcSEcCtD
Methyldopa—Dizziness—Etoposide—peripheral nervous system neoplasm	0.00021	0.000807	CcSEcCtD
Methyldopa—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000209	0.000803	CcSEcCtD
Methyldopa—COMT—Metabolism—NME1—peripheral nervous system neoplasm	0.000208	0.00238	CbGpPWpGaD
Methyldopa—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000206	0.000791	CcSEcCtD
Methyldopa—Mental disorder—Doxorubicin—peripheral nervous system neoplasm	0.000203	0.00078	CcSEcCtD
Methyldopa—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000202	0.000776	CcSEcCtD
Methyldopa—COMT—Metabolism—COX2—peripheral nervous system neoplasm	0.0002	0.00229	CbGpPWpGaD
Methyldopa—Rash—Etoposide—peripheral nervous system neoplasm	0.0002	0.000769	CcSEcCtD
Methyldopa—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.0002	0.000769	CcSEcCtD
Methyldopa—Headache—Etoposide—peripheral nervous system neoplasm	0.000199	0.000764	CcSEcCtD
Methyldopa—Flatulence—Doxorubicin—peripheral nervous system neoplasm	0.000199	0.000764	CcSEcCtD
Methyldopa—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000195	0.00075	CcSEcCtD
Methyldopa—Nausea—Etoposide—peripheral nervous system neoplasm	0.000188	0.000725	CcSEcCtD
Methyldopa—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000186	0.000714	CcSEcCtD
Methyldopa—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000186	0.000714	CcSEcCtD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—KNG1—peripheral nervous system neoplasm	0.000185	0.00212	CbGpPWpGaD
Methyldopa—COMT—trigeminal ganglion—peripheral nervous system neoplasm	0.000185	0.0792	CbGeAlD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000184	0.000709	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000184	0.0021	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—AKT1—peripheral nervous system neoplasm	0.000183	0.00209	CbGpPWpGaD
Methyldopa—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.00018	0.000694	CcSEcCtD
Methyldopa—Oedema—Epirubicin—peripheral nervous system neoplasm	0.000178	0.000684	CcSEcCtD
Methyldopa—Infection—Epirubicin—peripheral nervous system neoplasm	0.000177	0.00068	CcSEcCtD
Methyldopa—ADRA2A—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000177	0.00202	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—KNG1—peripheral nervous system neoplasm	0.000176	0.00202	CbGpPWpGaD
Methyldopa—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000174	0.000671	CcSEcCtD
Methyldopa—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.000174	0.00067	CcSEcCtD
Methyldopa—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000173	0.000664	CcSEcCtD
Methyldopa—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000172	0.00066	CcSEcCtD
Methyldopa—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000172	0.00066	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.00017	0.000656	CcSEcCtD
Methyldopa—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.000165	0.000633	CcSEcCtD
Methyldopa—COMT—brainstem—peripheral nervous system neoplasm	0.000164	0.0701	CbGeAlD
Methyldopa—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.000629	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000162	0.000623	CcSEcCtD
Methyldopa—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.000621	CcSEcCtD
Methyldopa—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.000161	0.00062	CcSEcCtD
Methyldopa—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.00016	0.000615	CcSEcCtD
Methyldopa—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.00016	0.000614	CcSEcCtD
Methyldopa—DDC—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.000158	0.00181	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—HGF—peripheral nervous system neoplasm	0.000154	0.00176	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—GNAS—peripheral nervous system neoplasm	0.000154	0.00176	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000154	0.000591	CcSEcCtD
Methyldopa—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000152	0.000585	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00015	0.000577	CcSEcCtD
Methyldopa—DDC—Metabolism—ENO2—peripheral nervous system neoplasm	0.000148	0.00169	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000148	0.00169	CbGpPWpGaD
Methyldopa—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000148	0.000568	CcSEcCtD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000145	0.00166	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000142	0.000546	CcSEcCtD
Methyldopa—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000541	CcSEcCtD
Methyldopa—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000541	CcSEcCtD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.00014	0.0016	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—HRAS—peripheral nervous system neoplasm	0.000135	0.00154	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000134	0.00154	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ENO2—peripheral nervous system neoplasm	0.000131	0.0015	CbGpPWpGaD
Methyldopa—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000131	0.000504	CcSEcCtD
Methyldopa—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.0005	CcSEcCtD
Methyldopa—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000128	0.000491	CcSEcCtD
Methyldopa—DDC—Metabolism—BCHE—peripheral nervous system neoplasm	0.000125	0.00143	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000122	0.00139	CbGpPWpGaD
Methyldopa—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000122	0.000468	CcSEcCtD
Methyldopa—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000121	0.000466	CcSEcCtD
Methyldopa—DDC—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000119	0.00136	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000119	0.00136	CbGpPWpGaD
Methyldopa—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000118	0.000454	CcSEcCtD
Methyldopa—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000452	CcSEcCtD
Methyldopa—DDC—Metabolism—TH—peripheral nervous system neoplasm	0.000118	0.00134	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000117	0.00134	CbGpPWpGaD
Methyldopa—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000113	0.000435	CcSEcCtD
Methyldopa—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000113	0.000433	CcSEcCtD
Methyldopa—Rash—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000431	CcSEcCtD
Methyldopa—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000112	0.000431	CcSEcCtD
Methyldopa—Headache—Epirubicin—peripheral nervous system neoplasm	0.000111	0.000429	CcSEcCtD
Methyldopa—COMT—Metabolism—BCHE—peripheral nervous system neoplasm	0.000111	0.00127	CbGpPWpGaD
Methyldopa—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000419	CcSEcCtD
Methyldopa—ADRA2A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000107	0.00122	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000106	0.00121	CbGpPWpGaD
Methyldopa—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000106	0.000406	CcSEcCtD
Methyldopa—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000402	CcSEcCtD
Methyldopa—COMT—Metabolism—TH—peripheral nervous system neoplasm	0.000104	0.00119	CbGpPWpGaD
Methyldopa—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000399	CcSEcCtD
Methyldopa—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000104	0.000399	CcSEcCtD
Methyldopa—COMT—Neuronal System—HRAS—peripheral nervous system neoplasm	0.000103	0.00118	CbGpPWpGaD
Methyldopa—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000103	0.000396	CcSEcCtD
Methyldopa—ADRA2A—Hemostasis—IFNB1—peripheral nervous system neoplasm	0.000103	0.00118	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000102	0.00116	CbGpPWpGaD
Methyldopa—Nausea—Doxorubicin—peripheral nervous system neoplasm	9.77e-05	0.000376	CcSEcCtD
Methyldopa—DDC—Metabolism—GNAS—peripheral nervous system neoplasm	9.6e-05	0.0011	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KNG1—peripheral nervous system neoplasm	9.55e-05	0.00109	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ABCB1—peripheral nervous system neoplasm	9.42e-05	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—trigeminal ganglion—peripheral nervous system neoplasm	9.41e-05	0.0403	CbGeAlD
Methyldopa—ADRA2A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	9.34e-05	0.00107	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	9.25e-05	0.00106	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GNS—peripheral nervous system neoplasm	8.62e-05	0.000985	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	8.53e-05	0.000975	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GNAS—peripheral nervous system neoplasm	8.52e-05	0.000974	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ABCB1—peripheral nervous system neoplasm	8.36e-05	0.000956	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—GNAS—peripheral nervous system neoplasm	8.35e-05	0.000954	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NME1—peripheral nervous system neoplasm	8.26e-05	0.000944	CbGpPWpGaD
Methyldopa—COMT—cerebellum—peripheral nervous system neoplasm	8.06e-05	0.0346	CbGeAlD
Methyldopa—ADRA2A—Hemostasis—HGF—peripheral nervous system neoplasm	7.96e-05	0.000909	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—COX2—peripheral nervous system neoplasm	7.95e-05	0.000909	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NTS—peripheral nervous system neoplasm	7.21e-05	0.000824	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CD55—peripheral nervous system neoplasm	6.91e-05	0.00079	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.04e-05	0.00069	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PTPN11—peripheral nervous system neoplasm	5.81e-05	0.000663	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	5.48e-05	0.000626	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.46e-05	0.000624	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.28e-05	0.000603	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ENO2—peripheral nervous system neoplasm	5.22e-05	0.000597	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.04e-05	0.000576	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.79e-05	0.000548	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BCHE—peripheral nervous system neoplasm	4.41e-05	0.000504	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—peripheral nervous system neoplasm	4.37e-05	0.0005	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A1—peripheral nervous system neoplasm	4.21e-05	0.000481	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TH—peripheral nervous system neoplasm	4.15e-05	0.000474	CbGpPWpGaD
Methyldopa—ADRA2A—cerebellum—peripheral nervous system neoplasm	4.11e-05	0.0176	CbGeAlD
Methyldopa—ADRA2A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.79e-05	0.000433	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NRAS—peripheral nervous system neoplasm	3.49e-05	0.000399	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GNAS—peripheral nervous system neoplasm	3.39e-05	0.000387	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.33e-05	0.000381	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ABCB1—peripheral nervous system neoplasm	3.32e-05	0.00038	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.24e-05	0.00037	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.09e-05	0.000353	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.83e-05	0.000324	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—peripheral nervous system neoplasm	2.67e-05	0.000305	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—peripheral nervous system neoplasm	2.59e-05	0.000296	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HRAS—peripheral nervous system neoplasm	2.55e-05	0.000292	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—peripheral nervous system neoplasm	2.3e-05	0.000263	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—peripheral nervous system neoplasm	2.25e-05	0.000258	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2e-05	0.000229	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	1.97e-05	0.000225	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.56e-05	0.000178	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.47e-05	0.000167	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.42e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.41e-05	0.000161	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.29e-05	0.000148	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.18e-05	0.000135	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.1e-05	0.000126	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—peripheral nervous system neoplasm	9.14e-06	0.000104	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.05e-06	0.000103	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.66e-06	9.89e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.64e-06	8.73e-05	CbGpPWpGaD
